PRESS-RELEASE ·Filed Mar 12, 2026
Press release · Earnings
Actionable Insight • Neutral
Traders should prepare for potential volatility following the March 26 earnings release and call, particularly focusing on revenue trends, cash burn, and progress toward commercial adoption of its AI-enhanced capsule technology.
Final — all horizons settled through T+60d
CV ▲ +27.17% at T+60d
NEUTRAL call +27.17% · α vs SPY +15.56% · entry $5.52 → $7.02
T+1d
-6.88%
call -6.88% · α -7.91%
$5.14
settled 8mo ago
T+5d
+24.46%
call +24.46% · α +26.57%
$6.87
settled 7mo ago
T+20d
+17.03%
call +17.03% · α +13.44%
$6.46
settled 7mo ago
T+60d
+27.17%
call +27.17% · α +15.56%
$7.02
settled 5mo ago
Price Chart
Loading chart...
Executive Summary
CapsoVision announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, followed by a conference call. The press release contains no actual financial data, serving only as a preview of the upcoming earnings announcement.
Key Facts
- CapsoVision will release Q4 and full-year 2025 financial results on March 26, 2026, after market close.
- A conference call and webcast are scheduled for the same day at 1:30 pm PT / 4:30 pm ET.
- No financial results, guidance, or operational updates were disclosed in this release.
- The company remains focused on its AI-enabled capsule endoscopy platform, including CapsoCam Plus® and the pipeline product CapsoCam Colon™.
Financial Impact
No financial data disclosed
Risk Factors
- Limited liquidity or high cash burn could raise near-term solvency concerns if disclosed in the upcoming report.
- Failure to show meaningful revenue growth or clinical adoption may pressure the stock despite the AI narrative.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Healthcare & Medical Devices
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255094 |
16 reports for CV
67% Hit rate @ T+60 Went positive at some point 4 of 8 best @ T+20▲ +10.53%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | 8-K | $6.92 | awaiting T+60 | — | $6.75 (−2.46%) |
Sep 28, 2026 29d ago | Press Release | $6.92 | awaiting T+60 | — | $6.75 (−2.46%) |
Sep 23, 2026 4w ago | Insider Cluster | $6.17 | awaiting T+60 | — | $6.75 (+9.40%) |
Sep 22, 2026 5w ago | Institutional Cluster | $6.30 | awaiting T+60 | — | $6.75 (+7.14%) |
Sep 18, 2026 5w ago | 424B5 | $6.70 | awaiting T+60 | — | $6.75 (−0.75%) |
Aug 24, 2026 9w ago | EFFECT | $5.83 | awaiting T+60 | — | $6.75 (−15.78%) |
Aug 13, 2026 10w ago | S-3 | $6.46 | awaiting T+60 | — | $6.75 (−4.49%) |
Jul 21, 2026 13w ago | Insider Buy | $6.91 $6.45 | ▼ −6.66% | ▼ −9.92% | $6.75 (−2.32%) |
Jul 10, 2026 15w ago | Insider Buy | $6.22 $6.50 | ▲ +4.50% | ▲ +0.51% | $6.75 (+8.52%) |
Jul 7, 2026 15w ago | Insider Buy | $6.13 $6.32 | ▲ +3.18% | ▲ +0.69% | $6.75 (+10.20%) |
Showing 10 of 16
US Market Status
Market Closed — Opens Wed (15h 40m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers